Associations of Vitamin D Levels and Vitamin D Receptor Genotypes with Patient-Reported Outcome/Disease Activity in Patients with Rheumatoid Arthritis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of rheumatoid arthritis, published as a randomized controlled trial.

The aim of this study is to evaluate the prevalence of vitamin-D insufficiency and vitamin-D receptor (VDR) polymorphisms in rheumatoid arthritis (RA) patients and its association with disease activity and patient reported outcomes (PROs).

Who Took Part

According to the abstract, 41 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Eighty-two individuals were included in a cross-sectional study (41 RA patients, 41 controls).

Prior to assessment, each patient completed a PRO questionnaire.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Serum vitamin-D levels and genotyping for VDR were assessed.

Vitamin-D deficient patients received vitamin-D supplementation.

What Was Measured

PubMed files the paper under topics including Arthritis, Rheumatoid, Cross-Sectional Studies, Dietary Supplements, Genotype, Patient Reported Outcome Measures, Polymorphism, Genetic and Polymorphism, Restriction Fragment Length.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 41 patients in people with rheumatoid arthritis.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Clinical laboratory), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Rheumatoid arthritis research.